Search

Facilitating knowledge transfer during Australia’s COVID-19 vaccine rollout: an examination of ‘Functional Dialogues’ as an approach to bridge the evidence–policy gap

Our interdisciplinary team initiated a project to inform the COVID-19 vaccination programme. We developed a novel research co-creation approach to share emerging findings with government. 

The Kids Research Institute Australia launches Covid-19 booster research to inform Australia’s vaccine policy

Optimising our national Covid-19 vaccine program could be one step closer thanks to new research now underway at The Kids Research Institute Australia investigating the most effective, long-term strategies for booster vaccinations.

COVID-19 risks explained for babies, children and pregnant women

Many parents may be feeling anxious and confused about what COVID-19 means for pregnant women, babies and children.

It’s not just physical illness that will have an impact: A ground-breaking study is investigating the effect of COVID-19 on community wellbeing

In an Australian-first study, researchers at The Kids Research Institute Australia are investigating the effects of COVID-19 on the wellbeing of more than 2,000 families in the northern suburbs of Perth, measuring their perceived stress, financial hardship and family functioning during the pandemic.

Community immunity: Developing a sensitive and specific SARS-CoV-2 antibody test

Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group

UV light and COVID-19

Investigator: Nisali Gamage Project description We critically review new studies which are emerging that report findings related to the effects of UV

Western Australian health care workers’ views on mandatory COVID-19 vaccination for the workplace

Health care workers (HCWs) are at an increased risk of catching and spreading Coronavirus Disease 2019 (COVID-19) compared with the general community, putting health systems at risk. Several jurisdictions globally have mandated or are looking to mandate COVID-19 vaccines for this cohort, but little is known about the acceptability of this measure, especially in different contexts, and there is little qualitative data to explore nuance, depth, and the reasons behind HCWs’ opinions.

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review

The search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non–coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results.

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial

We previously reported the efficacy of the adjuvanted-protein COVID-19 vaccine candidate S-Trimer (SCB-2019) in adults who showed no evidence of previous exposure to SARS-CoV-2. In this study, we aimed to investigate the extent of protection afforded by previous exposure to SARS-CoV-2 on subsequent COVID-19 infection, as well as the efficacy, safety, and reactogenicity of SCB-2019 in participants who were enrolled in the Study.

The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021

Peter Britta Richmond Regli-von Ungern-Sternberg AM FAHMS MBBS MRCP(UK) FRACP MD, PhD, DEAA, FANZA Head, Vaccine Trials Group Chair of Paediatric